Open AccessSuccessful treatment of a high-risk nonseminomatous germ cell tumor using etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine: A case report
Author(s) -
Jina Yun,
Sang W. Lee,
Sung Hee Lim,
Se H Kim,
Chan K Kim,
Seong K Park
Publication year - 2020
Publication title -
world journal of clinical cases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.368
H-Index - 10
ISSN - 2307-8960
DOI - 10.12998/wjcc.v8.i21.5334
Subject(s) - medicine , etoposide , choriocarcinoma , regimen , vincristine , cyclophosphamide , germ cell tumors , chorioepithelioma , oncology , chemotherapy , methotrexate , surgery , gastroenterology
Choriocarcinoma is an infrequent entity and the most aggressive subtype of germ-cell tumors. Because of early metastatic spread and rapid disease progression, choriocarcinoma patients display poor prognosis. Although etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine (EMA-CO) regimen is widely used to treat gestational trophoblastic tumors in females, its role in treating male choriocarcinoma is seldom reported.